SUMMIT, NJ– Merck Animal Health today introduced Coccivac® Scheduler, an iPad® app, which will help poultry producers create best management practices protocols focused on minimizing the costly and persistent threat of coccidiosis. The most significant and common intestinal poultry disease, coccidiosis costs global poultry producers an estimated $300 million annually in production losses.1
Working with a Merck Animal Health sales representative, producers can use the Coccivac Scheduler to collect trend data, as well as connect past coccidiosis programs with performance issues. This will help provide insights to help minimize losses and maximize flock health. Utilizing the features of the app, producers also will be able to develop a five-year coccidiosis management plan, including vaccination and rotation programs, that will help support their efforts to more proactively manage the disease on their operations.
"By the time producers notice a lack of effectiveness in their current coccidiosis programs, the health of their flocks, as well as the profitability of the operation, could be impacted," said Charles Broussard, D.V.M., associate director, scientific marketing affairs at Merck Animal Health. "Coccivac Scheduler is a valuable tool for producers that utilize data and trends to reveal shortfalls in current programs – such as lack of efficacy in current in-feed anticoccidial products – before there is a decrease in flock performance. Identifying a problem early or using proactive measures to help minimize its impact saves time, money and birds."
The easy-to-use app includes a comprehensive list of available in-feed anticoccidial products used to combat coccidiosis, as well as the Merck Animal Health Coccivac line of vaccines, which help prevent coccidiosis in chickens when vaccinated by spray at 1 day of age. While an in-feed medication protocol has been the industry standard, vaccination is critical to a successful, long-term coccidiosis management program.
Based upon producers' inputs, the Coccivac Scheduler is used to create a customized best practices program that addresses the timing of vaccination in rotation with other products. It helps eliminate traditional variables such as overuse of in-feed anticoccidials and not rotating chemicals from different classes which are often seen with standard coccidiosis management regimens. This approach allows producers to develop long-term disease management strategies to achieve profitable programs that deliver more consistent results.
"At Merck Animal Health, we are committed to helping poultry producers protect their flocks from disease and have listened to their needs with regard to this health risk," said Dr. Broussard. "With their needs in mind, the Coccivac Scheduler was developed – putting the power of designing an effective coccidiosis-control program in their hands and helping them address the very real challenges they face daily in their operations."
Producers interested in using Coccivac Scheduler will begin with a consultation with a Merck Animal Health representative to review the poultry operations' past and current programs, preferences for product usage and management practices. For more information about Coccivac Scheduler, producers and veterinarians can contact their Merck Animal Health representative.
About Merck Animal Health
Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.
Merck Forward-Looking Statement
This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2013 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Source: Merck Animal Health